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Effects of gastrointestinal hormones on transport by peritoneal
dialysis. Because the gastrointestinal hormones are known to di-
late the splanchnic vasculature, their effects on transport of wa-
ter and solutes during peritoneal dialysis were studied in an ex-
perimental model, the rabbit. In unanesthetized rabbits, dialy-
sate volume was calculated by isotope dilution, and clearances
were estimated by dialysate/plasma concentration ratio factored
by minute volume. With isotonic dialysis solution, the mean in-
crement in dialysate volume per minute of intraperitoneal dwell
was 0.19 mi/kg/mm, and mean clearances of creatinine and urea
were 0.71 and 0.90 mI/kg/mm, respectively. When administered
intravenously, secretin significantly augmented osmotically in-
duced water flux, but not when given intraperitoneally. Neither
glucagon nor cholecystokinin affected dialysate volume. Intra-
venously, but not intraperitoneally, glucagon increased perito-
neal clearances of creatinine and urea to more than 150% of con-
trol values. Neither cholecystokinin nor secretin augmented sig-
nificantly peritoneal mass transport when given by either route.
The data suggest that the site of action is the endothelial surface
of the membrane, that the mechanisms of augmenting transport
involve increased permeability and/or surface area, and that
agents which combine an increase in mass transport and capil-
lary filtration coefficient may be clinically useful.
Effets des hormones gastro-intestinales sur les transports au cours
de Ia dialyse péritonéale. Du fait que les hormones gastro-in-
testinales dilatent le territoire vasculaire splanchnique, leurs ef-
fets sur les transports d'eau et de substances dissoutes au cours
de Ia dialyse péritonéale ont été étudiés sur un modèle ex-
périmental, le lapin. Chez des lapins éveillés le volume de dialy-
sat a ëté calculé par dilution isotopique et les clearances par le
rapport de concentration dialysat/plasma multiplié par le debit.
Avec une solution isotonique l'augmentation moyenne du vol-
ume du dialysat par minute de cycle intrapéritoneal est de 0,19
mi/kg/mm et les clearances moyennes de Ia créatinine et de
l'urée sont de 0,71 et 0,90 ml/kg/min, respectivement. La sdcré-
tine administrée par voie intraveineuse augmente le flux os-
motique d'eau. Cet effet n'est pas observe si la sécrétine est ad-
ministrée par voie intrapéritonéale. Le glucagon, par voie intra-
veineuse mais non intraperitoneale, augmente les clearances de
Ia créatinine et de l'urée a plus de 150% des valeurs contrôles.
Ni Ia cholecystokinine, ni Ia sécrétine n'augmentent le transport
massique péritonéal quelle que soit Ia voie d'administration. Ces
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constatations suggèrent que le site de l'action est Ia face endo-
théliale de Ia membrane, que les méchanismes de l'augmentation
des transports impliquent une augmentation de perméabilité et/
ou de la surface d'echange et que les agents qui induisent ala fois
une augmentation de transport de substances et du coefficient de
filtration capillaire peuvent étre utiles en clinique.
Recently, it has been demonstrated that perito-
neal mass transport can be augmented by intra-
peritoneal instillation of pharmacologic vasodilators
into dogs [1], rabbits [2-4], and uremic patients with
or without systemic vascular disease [5—7]. Evi-
dence that augmented mass transport is not the Fe-
suit of nonspecific mesothelial irritation includes
the divergent effects of potent diuretics on perito-
neal transport of cations and of nitrogenous metab-
olites [8] and the demonstration that clearances in-
crease after parenterai as well as local administra-
tion of dipyridamoie [7]. Accordingly, investiga-
tions have focused on the effects of vasoactive
drugs on peritoneal clearances rather than on agents
that might affect permeability itself. Because all
drugs studied and used clinically for this purpose
are potentially hazardous, additional study of fac-
tors affecting peritoneal clearances seems justified
with the long-term goal of identifying the ideal agent
for safely augmenting transport.
The gastrointestinal hormones, glucagon, secre-
tin and cholecystokinin, are peptides that selective-
ly dilate the splanchnic vasculature [9]. Accord-
ingly, we evaluate the effect of these hormones on
peritoneal mass transport in an experimental ani-
mal, the rabbit. Because the gastrointestinal hor-
mones are so large (glucagon, 3484 daltons; secre-
tin, 3055 daltons; and cholecystokinin, 3918 dal-
tons) that they do not readily permeate the
peritoneum, the route of administration should de-
termine the surface to which the hormone is ex-
posed, and the site at which a hormone acts can be
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delineated. In these studies, cholecystokinin does
not augment peritoneal mass transport or osmotic
water flux when given by either route. Glucagon,
however, given intravenously, but not intra-
peritoneally, accelerates transport significantly, and
intravenous secretin augments osmotically induced
water flux.
Methods
Peritoneal dialyses were conducted in unanesthe-
tized, female, New Zealand white rabbits that
weighed between 3.5 and 4.8 kg each. With bent
front paws and extended hind limbs restrained by
cloth cuffs on a board, the animals are docile, but
readily extrude an indwelling catheter. Accord-
ingly, dialysis was initiated by instilling, for about 4
mm, into the peritoneum through a 16-gauge needle,
75 mI/kg of commercially available dialysis solution
containing: sodium, 141 mEq/liter; calcium, 3.5
mEq/liter; magnesium, 1.5 mEq/liter; chloride, 101
mEq/liter; lactate, 45 mEq/liter; and glucose, 1.5 g/
dl (isotonic) or 4.25 g/dl (hypertonic), at room tem-
perature. Autologous protein labeled with 203Hg,
which had been shown to be more than 99% protein-
bound, was added to the instilled dialysis solution.
A protein concentration of 10 to 30 mg/dl has been
sufficient to achieve radioactivity exceeding ten
times background. Aliquots of dialysate were sam-
pled at precisely timed, 12-mm intervals after the
midpoint of the instillation for determination of con-
centrations of creatinine [10] and urea [11] and for
measurement of radioactivity. Plasma solute con-
centrations of blood sampled from the artery of the
ear before or after the procedure have been as-
sumed to change inconsequentially during the
course of a 60-mm dialysis. (In separate, unpub-
lished studies, we determined that after 60 mm of
dialysis, plasma urea decreased to a mean of 93%
and plasma creatinine to 98% of the initial concen-
tration).
Dialysate volume at any given time (t) was deter-
mined by dilution of the instilled labeled protein ac-
cording to the formula Vt = V0 x cpm0Icpm. Al-
though dialysate volume should increase ex-
ponentially, during the first 60 mm of study the
observed data fit a linear regression sufficiently well
to use this simpler equation in determining the vol-
ume.
Peritoneal clearances were calculated as C =
DIP x Vt, that is, dialysate/plasma concentration
ratio factored by volume per unit time, and ex-
pressed as milliliter per kilogram per minute. As the
duration of intraperitoneal dwell increases, dialy-
sate concentrations asymptotically approach plas-
ma water concentrations. Thus, clearances de-
creased as intraperitoneal dwell was prolonged, and
the relationship of clearance to time was calculated
for each experiment by linear regression, allowing
correction of clearances to a constant time. Fur-
thermore, clearances increase with time, that is, as
the animals mature, possibly related to increased
peritoneal surface area [12]. Accordingly, all exper-
imental clearances were compared to the control
clearances performed immediately before and after
the study rather than to the mean of all control mea-
surements.
Sixteen rabbits were studied. Control clearances
were measured on each animal with 1.5% dextrose
dialysis solution. In addition, three of the rabbits
underwent a series of dialyses with 4.25% dextrose
dialysis solution with or without the addition of gas-
trointestinal hormones. With both isotonic and hy-
pertonic dialyses, the effect of these hormones on
osmotic water flux was assessed. Because it has
been shown that heterologous protein when used as
the dilution indicator gives spuriously high results
[12], volume studies on four animals performed
with such a label were not considered reliable, and
only studies with autologous protein were used.
With all isotonic dialyses, clearances of creatinine
and urea were measured.
Glucagon (Eli Lilly Co.) was administered intra-
peritoneally with the dialysis solution in nine dial-
yses in seven rabbits at a dose of 0.03 mg/kg, and in
five dialyses in five of these rabbits at 0.125 mg/kg.
Eight dialyses in six of these rabbits were per-
formed immediately after an intravenous bolus in-
jection of 0.03 mg/kg of glucagon, and three dialyses
in three animals followed intravenous administra-
tion of 0.125 mg/kg of glucagon.
Secretin (Warren-Teed) was administered intra-
peritoneally with the dialysis solution in eight dial-
yses in eight rabbits at a dose of 10 U/kg. Three
rabbits underwent a single peritoneal dialysis, each
immediately after intravenous administration of 5
U/kg of secretin, an intravenous bolus dose of 10 UI
kg of secretin preceded eight peritoneal dialyses in
five rabbits, and a dose of 22.5 U/kg was adminis-
tered to each of four rabbits immediately prior to a
single dialysis.
A single dialysis was performed in six rabbits
with the intraperitoneal administration of 2.5 pg/kg
of cholecystokinin (cholecystokinin octapeptide,
Squibb), and eight dialyses in eight rabbits were
carried out immediately after intravenous bolus in-
jection of 2.5 pg/kg of cholecystokinin.
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None of the hormones interfered with the chem-
ical assays of creatinine or urea. From all measure-
ments of creatinine in dialysate, 0.2 mg/dl was sub-
tracted to offset the interference by glucose in iso-
tonic dialysis solution, and with hypertonic
dialyses, only urea clearance was determined.
Mean clearances corrected for the duration of in-
traperitoneal dwell were calculated for each animal
for control and experimental dialysis. The mean of
five clearance measurements under control condi-
tions before the experimental dialysis and of five
measurements after were averaged. This average
mean control value was compared to the mean of
five experimental measurements for a given hor-
mone by each route by Student's paired t test [13].
Results
With 33 control isotonic peritoneal dialyses, the
mean calculated increment in dialysate volume with
autologous 203Hg-protein was 0.19 mI/kg/mm in con-
trol dialyses in 14 rabbits, comparable to the value
0.17 mllkg/min that we have previously reported for
control dialysis in rabbits [12]. With intraperitoneal
administration of secretin, cholecystokinin, and
glucagon, the increments in dialysate volume aver-
aged 0.20, 0.22, and 0.18 mllkglmin, respectively,
which were not significantly different from controls,
each P > 0.1 (Fig. I). The mean volume increment
after secretin was given intravenously was 0.29 mu
kg/mm (P <0.05 above control), whereas mean os-
motic water flux with cholecystokinin (0.18 mI/kg!
mm) and with glucagon (0.20 ml/kg/min) did not ex-
ceed control values (P > 0.1). By the Wilcoxon
rank sum test, the ratio experimental/control vol-
ume with intravenous secretin exceeded the ratio of
the other five experimental groups (P < 0.01).
When hypertonic dialysis solution was instilled, the
mean increment in dialysate volume in 12 control
dialyses in three rabbits was 0.54 mI/kg/mm. With
glucagon 0.03 mg/kg added to hypertonic dialysis
solution, the volume increment averaged 0.61 mI/
kg/mm in two rabbits, whereas with intraperitoneal
cholecystokinin, the increment in volume averaged
0.29 mI/kg/mm in two animals; and when cholecys-
tokinin was administered intravenously before hy-
pertonic peritoneal dialysis, the increment in vol-
ume was 0.48 mI/kg/mm in two rabbits. None of
these hypertonic dialysis-volume studies showed
sufficiently high volume increments to encourage us
to explore further this method for demonstrating
augmentation of osmotic water flux.
With isotonic dialysis solution, control creatinine
clearances ranged from 0.36 to 1.16 mI/kg/mm, and
urea clearances from 0.37 to 2.01 mllkg/min, aver-
aging 0.71 and 0.90 mI/kg/mm, respectively. As in-
traperitoneal dwell of dialysate was prolonged,
mean control clearances decreased by 0.006 and
0.008 mI/kg/mm per minute of dwell. Accordingly,
before comparison of control and experimental dial-
ysis, all clearances were corrected to a constant in-
traperitoneal dwell time. Moreover, because there
was considerable variation in clearances from rab-
bit to rabbit, and in a given animal clearances in-
creased with time, experimental clearances were
compared by paired t test to the mean of the control
clearances that preceded and followed the study in
the identical animal.
With intraperitoneal glucagon (0.03 mg/kg), mean
creatinine and urea clearances in seven rabbits were
0.69 and 0.92 ml!kg/min, respectively, not signifi-
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Fig. 1. Slope showing the minute increment in dialysate volume during control
isotenic peritoneal dialyses and with intraperitoneal (i.p.) or intravenous (i.v.)
administration of secretin (S), cholecystokinin (C), or glucagon (G). Intraven-
ously secretin increased osmotically induced water flux significantly (P < 0.05).
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cantly different (P > 0.1) from the paired control
values 0.65 and 0.73 mI/kg/mm (Fig. 2). When the
same dose, however, was given intravenously im-
mediately prior to initiating peritoneal dialysis,
clearances increased significantly above controls to
1.02 mI/kg/mm (creatinine, P < 0.02) and 1.44 ml!
kg/mm (urea, P <0.01), and above the values with
intraperitoneal glucagon (each, P <0.05). A higher
intravenous dose (0.125 mg/kg) did not augment
creatinine (1.09 mllkg/min) or urea transport (1.50
mi/kg/mm) further (P > 0.1), but clearances re-
mained significantly above control values in the
three animals studied (P < 0.05). With the higher
dose of glucagon administered intraperitoneally,
creatinine and urea clearances (1.00 and 1.23 mi/kg!
mm, respectively) exceeded control values (P <
0.01, <0.05), but not those achieved with the lower
dose intravenously (P > 0.1) or even intraperito-
neally (P > 0.1).
By either route of administration, glucagon in-
creased the slope, relating clearance to the duration
of intraperitoneal dwell of dialysis solution. Figure
3 relates creatinine clearance to intraperitoneal
dwell in the three animals that underwent study of
the effects of each dose of glucagon by each route.
A similar effect was seen with glucagon influencing
urea clearance. The control slope was —0.007,
whereas with intraperitoneal glucagon, it was
—0.012, and with intravenous glucagon, —0.019 ml!
kg/mm per minute of dwell, each significantly great-
er slopes (P < 0.05, P < 0.02).
The mean ratio creatinine clearance/urea clear-
ance in control dialysis was 0.79, which is in accord
with our previously published values in rabbits [12]
and in patients [7, 14]. The controls in the glucagon
series of experiments had a higher ratio, 0.89. With
intraperitoneal glucagon, the clearance ratio was
0.78, and with intravenous glucagon, it was 0.72.
These values are not significantly below controls (P
> 0.1).
Figure 4 shows the effect of cholecystokinin on
peritoneal clearances. Mean control values were
0.68 mi/kg/mm (creatinine) and 1.03 mllkg/min
(urea). With cholecystokinin, both intraperitoneally
and intravenously, the values were on the average
15% higher, but none of the changes were signifi-
cant (each P > 0.1).
Clearances with glucagon or cholecystokinin
were calculated with the identical dialysate volume
as for control clearances, because there was no dif-
ference detected in the volumes calculated by iso-
tope dilution with or without these hormones.
Therefore, the increased clearance with glucagon
resulted from an increased dialysate/plasma con-
centration ratio.
With intraperitoneal secretin, and with the identi-
cal volume as with control studies, mean creatinine
and urea clearances were 0.68 and 0.98 mllkg/min,
respectively, not significantly different from control
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Fig. 2. Mean peritoneal clearances of urea and creatinine show-
ing an increase significantly above control when low-dose"
glucagon (0.03 mg/kg) is given intravenously but not intra-
peritoneally.
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Fig. 3. Creatinine clearance showing decreases as intra-
peritoneal dwell of dialysate is prolonged. This slope is greater
when glucagon is administered than it is during control dialyses.
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Fig. 5. Peritoneal clearances of urea and creatinine showing in-
creases of up to 20% with secret in that are not statistically signif
icant. The steeper slopes (intravenous) take into account the in-
creased dialysate volume resulting from secretin, whereas the
lower lines and points do not.
values in these rabbits, 0.66 and 0.82 mI/kg/mm
(each P > 0.1). Following intravenous secretin,
mean clearances of creatinine and urea, calculated
with the mean volume estimated in these particular
secretin studies, were 0.83 and 1.16 mI/kg/mm, re-
spectively, which were not significantly higher (P>
0.1) than the corresponding control values of 0.73
and 1.03 mllkg/min (Fig. 5). With the same dialysate
volume as in control studies, calculated clearances
after intravenous secretin would be 0.79 and 1.11
mllkg/min, respectively.
By the Wilcoxon rank sum test, the ratio experi-
mentallcontrol clearances with intravenous gluca-
gon was significantly higher for both creatinine (P <
0.025) and urea (P < 0.01) than the ratios of the oth-
er five experimental protocols.
With hypertonic dialysis, mean control urea
clearance was 1.05 mllkg/min. When glucagon was
given intraperitoneally during such dialyses, mean
urea clearance was 1.05 mllkglmin, whereas intra-
peritoneal and intravenous cholecystokinin resulted
in mean clearances of 0.80 and 1.11 mllkg/min, re-
spectively.
Discussion
These studies have the overall aim of character-
izing more thoroughly the physiologic barriers to
solute and water flow across the peritoneal capillary
wall and mesothelium. Such fundamental informa-
tion coupled with knowledge of the types of com-
pounds that augment transport and the mechanisms
involved should allow design of therapeutic addi-
tives to enhance the efficiency of peritoneal dial-
ysis.
Although neither secretin nor cholecystokinin
augmented peritoneal mass transport, glucagon did
increase clearance of creatinine and urea signifi-
cantly, both when given intravenously and when
given in very high doses intraperitoneally. Because
glucagon should traverse the peritoneum very slow-
ly because of its large size [15], the greater ef-
fectiveness when given intravenously than when in-
traperitoneally is interpreted to indicate that the
endothelial, not the serosal surface, is the site of
action. This interpretation assumes that the capil-
lary wall is the more important diffusion barrier. Al-
ternatively, the capillary side of the mesothelium
could be the site of action, a less likely explanation,
since glucagon is a known splanchnic vasodilator
[16]. It must also be assumed that glucagon distrib-
utes very rapidly within plasma. Because plasma
volume of the rabbit should be close to 75 mllkg, the
concentration at the two surfaces should have been
comparable in the two types of studies, at identical
doses. Drugs that have been reported to augment
peritoneal mass transport when given intraperito-
neally are small solutes that should be absorbed
across the peritoneum rapidly [12]. High concentra-
tions locally may selectively dilate the splanchnic
vasculature, whereas when given systemically, pe-
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Fig. 4. Peritoneal clearances of urea and creatinine showing
slight increments when cholecystokinin is administered that are
not statistically significant.
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ripheral vasodilation may predominate. Glucagon,
however, doesn't traverse the membrane readily,
but selectively dilates the splanchnic vasculature.
The augmentation of peritoneal mass transport is
not only a consistent observation, but also a change
of considerable magnitude, because the mean clear-
ances with glucagon were as high as 157 and 197%
of the control values.
The doses used were pharmacologic, and the re-
sults in these studies may not be translated to the
hyperglucagonemia seen in patients with renal fail-
ure, which may in part be immunoreactive, but not
physiologically active [17—19]. Renal failure in-
creases plasma glucagon from about 100 pg/ml to
about 250 pg/ml, whereas peak equilibrium concen-
trations, that is, after distribution in plasma, but be-
fore elimination, in these studies would be about
400 ng/ml. Although the half life of glucagon is nor-
mally less than 20 mm, very high concentrations
would persist throughout the 60-mm study period.
Based on an estimated dialysate concentration of
400 ng/ml and a predicted peritoneal clearance of
0.04 mI/kg/mm, the intraperitoneal administration
of glucagon should represent an infusion of about
16 ng/kg/min, which in view of the rapid elimina-
tion, would achieve plasma concentrations in the
range of 1 to 2 ng/ml. Intraperitoneal administration
resulted in glucagon concentrations of 400 and 1600
ng/ml on the serosal side of the membrane.
Even though our study design did not include
clearance measurements of solutes of very diver-
gent molecular size, there is a reproducible separa-
tion of the clearance of urea and creatinine, which
must be attributed to permeability/surface area. The
transport rate of both of these solutes increased
proportionately because the clearance ratio did not
fall significantly. Therefore, the enhancement of
mass transport due to intravenous glucagon should
not be interpreted as simply the result of increased
solute delivery accompanying higher blood flow as
creatinine flux is more permeability/area limited
than urea.
Although glucagon increased solute transport,
and by implication peritoneal area/permeability, it
did not increase net water flux. This paradox may
be explained by increased glucose influx with a re-
sultant loss of the osmotic gradient, although water
flux per unit of osmotic gradient is increased. Other
factors that might contribute to the constancy of
water flux include changes in hydraulic forces,
glucagon-induced hyperglycemia, and a decrease in
the capillary filtration coefficient [20]. We have not
tested these possibilities.
On the other hand, secretin did increase the net
water flux significantly, in accord with prior studies
that demonstrate an increase in capillary filtration
coefficient when secretin is given to cats [20]. It is
not clear whether increased water flux results from
augmented water permeability of the capillary, in-
creased surface area, possibly of more water per-
meable segments, or increased capillary hydrostatic
pressure, that is, arteriolar dilatation, while venular
resistance remains unchanged.
The contribution of net water flux to peritoneal
clearance for small solutes is relatively small. Note
the small difference between the clearance calcu-
lated with the increased volume and with control
volumes illustrated in Fig. 5. At the mean duration
of intraperitoneal dwell, the increment in dialysate
volume with intravenous secretin was 10.4 ml/kg,
significantly higher than the control increment
6.8 ml/kg, but the relative difference in total dialy-
sate volume (85.4 mI/kg compared to 81.8 ml/kg) is
less obvious. Clearances are determined in this
model more by the concentration ratio than by
changes in dialysate volume.
Cholecystokinin not only augments gallbaldder
motility and pancreatic enzyme secretion [21, 22],
but it also induces splanchnic vasodilation. Our
studies, however, do not support vasodilation of
that portion of the splanchnic vasculature respon-
sible for peritoneal solute and fluid exchange.
The physiologic effects of secretin and cholecys-
tokinin are more easily detected after a bolus intra-
venous injection than during a brief continuous in-
fusion [23] despite their short half lives [24], so we
used this technique of administration. Although se-
cretin and cholecystokinin increase hepatic blood
flow on a molar basis to a greater extent than gluca-
gon does [24], the superior mesenteric arterial flow
increases by as much as 170% when glucagon is ad-
ministered [25].
Glucagon affected solute transport to a greater ex-
tent during the early phase of a dialysis exchange,
as reflected by the steeper slopes relating peritoneal
clearances to the duration of intraperitoneal dwell.
As intraperitoneal dwell is prolonged, solutes equi-
librate with plasma, and rates of diffusion are not as
clearly separated. Accordingly, augmentation of
peritoneal transport is recognized most easily with
short exchanges or during the early part of an ex-
change as we have observed.
We did not monitor the animals specifically for
pyrogenic reactions to the hormones. It is unlikely
that such a nonspecific mechanism accounts for the
results, because repeated studies on the same ani-
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mals showed neither tolerance nor enhancement,
systemic vascular effects might offset effects on the
splanchnic vasculature, and the separation of the ef-
fects of the different hormones on solute and on wa-
ter fluxes suggests specific responses.
Augmented peritoneal transport due to these hor-
mones does not have apparent clinical application,
but it may clarify mechanisms whereby efficiency of
peritoneal dialysis can be enhanced. Future studies
may seek to identify drugs that combine the proper-
ties of glucagon and secretin, possibly with agents
that affect mesothelial permeability as well. Before
such drugs are used for clinical peritoneal dialysis,
it should be verified that the peritoneum of uremics
responds as normals do, an assumption in this
study.
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